Levi & Korsinsky notifies investors that it has commenced an investigation into Telix Pharmaceuticals Limited (NASDAQ: TLX) concerning potential violations of the federal securities laws.
On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix’s New Drug Application for TLX101-CDx (“Pixclara”). The FDA indicated “additional confirmatory clinical evidence is required to progress the application.” Following this news, Telix’s stock price fell by $1.47 per share to open at $17.33 per share.
If you suffered a loss on your Telix Pharmaceuticals Limited securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





